Meridian Wealth Management LLC Acquires Shares of 8,725 Hims & Hers Health, Inc. (NYSE:HIMS)

Meridian Wealth Management LLC bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 8,725 shares of the company's stock, valued at approximately $211,000.

Several other large investors have also recently added to or reduced their stakes in HIMS. Crewe Advisors LLC purchased a new stake in shares of Hims & Hers Health in the 4th quarter valued at approximately $28,000. Raleigh Capital Management Inc. increased its position in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 1,100 shares during the last quarter. Smartleaf Asset Management LLC increased its position in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares during the last quarter. US Bancorp DE increased its position in shares of Hims & Hers Health by 346.7% in the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock valued at $47,000 after purchasing an additional 1,508 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in shares of Hims & Hers Health in the 4th quarter valued at approximately $48,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Piper Sandler upped their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a report on Tuesday, February 25th. Canaccord Genuity Group upped their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Leerink Partners upped their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a report on Tuesday, February 25th. TD Cowen restated a "buy" rating and issued a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Finally, Bank of America restated an "underperform" rating and issued a $21.00 target price on shares of Hims & Hers Health in a report on Thursday. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $37.23.

Remove Ads

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded up $1.62 during midday trading on Friday, reaching $36.01. 23,509,501 shares of the company traded hands, compared to its average volume of 13,182,499. The firm has a market cap of $8.00 billion, a PE ratio of 81.85 and a beta of 1.37. The stock's 50-day simple moving average is $37.64 and its 200-day simple moving average is $27.60. Hims & Hers Health, Inc. has a 12 month low of $11.20 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Transactions at Hims & Hers Health

In related news, insider Soleil Boughton sold 4,152 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the sale, the insider now directly owns 157,345 shares in the company, valued at $9,549,268.05. This represents a 2.57 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Oluyemi Okupe sold 18,959 shares of the company's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $25.77, for a total value of $488,573.43. Following the sale, the chief financial officer now owns 132,578 shares of the company's stock, valued at approximately $3,416,535.06. This represents a 12.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,062,011 shares of company stock worth $36,892,724 in the last 90 days. Corporate insiders own 17.71% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.